Geriforte) was tested with this model, and it was found to be a strong antistress adaptogen. The long-term administration of CIHP to rats (6 weeks) at a dose of 1 mg/g body weight increased the duration of time to reach a core temperature of 23°C (73°F) by 72 percent and decreased the recovery time by 46 percent. Results obtained with this experimental animal model suggest that CIHP administration induces significant thermoregulatory tolerance to cold and hypoxia.
In a subsequent placebo-controlled, double-blind trial of CIHP, human male volunteers, who remained at extreme altitudes (4,800 to 6,000 m [15,748 to 19,684 ft]) for a period of 3 or 6 months, were tested for various indices at 3,050 m (10,007 ft) prior to their induction to higher altitudes (4,800 to 6,000 m [15,748 to 19,684 ft]) and again 6 months after their return to the plains after the high-altitude stay. Environmental stresses at the higher altitudes consisted of hypobaric hypoxia (420 to 335 mm Hg), low temperature (-40° to 0°C [-40° to 32°F]), high-velocity winds (0 to 150 km/h), and sunlight, which created intense heat, blinding reflection on the snow, and increased ultraviolet and ionizing radiation. The psychological stresses consisted of isolation, uncertainty of weather conditions, and enhanced physical exertion.
A randomly assigned group of 14 men remained and worked in the high mountains for a period of 3 months, and a second group of 30 men remained for 6 months. Each group was further divided at random into two subgroups. The subgroups were given placebo or CIHP tablets. The volunteers were examined a second time at 3,050 m (10,007 ft) within 7 days of their descent from the high mountains. The third set of data was recorded 6 months after returning to the plains from altitude.
During the human subjects' prolonged stay and work for 3 months in the high mountains (4,800 to 6,000 m), the placebo-administered group lost 3.3 percent of their body weight. The group given CIHP lost 2.67 percent of their body weight. After returning from high altitude and staying 6 months in the plains, subjects gained body weight, which exceeded their initial body weight by 1.65 percent and 4.75 percent in placebo and CIHP groups, respectively. These data show that the administration of adaptogens in a high-altitude environment helped to maintain subjects' body weight and, on returning to the plains, helped further to increase body weight, even though the administration of adaptogen was discontinued after the return from high altitude. However, in subjects who stayed 6 months at high altitude, the loss in body weight could not be arrested by CIHP administration. Gain in body weight during their stay in the plains also did not exceed significantly their initial body weight.
The effect of high altitude on some of the higher cognitive functions of humans indicated that the perception and concentration functions deteriorated after a stay of 3 months in the high mountains. These functions recovered fully on return to lower altitude within 6 months. In those subjects who were given CIHP at high altitude, a deterioration in perception was not observed. Deterioration in concentration was observed in subjects give CIHP (p < 0.05).